Arthritis Monoclonal Antibodies Market Report 2026

The arthritis monoclonal antibodies market size has grown strongly in recent years. It will grow from $66.45 billion in 2025 to $71.66 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increasing prevalence of rheumatoid arthritis, limited effectiveness of conventional dmards, growing awareness of biologic therapies, expansion of hospital-based rheumatology care, rising healthcare expenditure.

The arthritis monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $98.46 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to development of next-generation monoclonal antibodies, increasing launch of biosimilars, growth in personalized immunotherapy approaches, rising aging population with arthritis conditions, improving reimbursement policies for biologics. Major trends in the forecast period include rising adoption of biologic therapies for autoimmune arthritis, increasing preference for targeted monoclonal antibody treatments, growth in early and aggressive treatment approaches, expansion of biosimilars for arthritis monoclonal antibodies, improved patient access through hospital and specialty clinics.

The growing number of approvals for personalized medicines is expected to drive the expansion of the arthritis monoclonal antibody market in the coming years. Personalized medicines are therapeutic products or treatments specifically tailored to individual patients and are developed based on genetic profiles, biomarkers, phenotypic traits, or psychosocial characteristics that help predict how a patient will respond to therapy. Monoclonal antibodies represent an advanced class of drugs that align closely with the personalized medicine approach and offer the potential to enhance treatment effectiveness and healthcare efficiency. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization that supports the adoption of personalized medicine, a report highlighted 26 newly approved personalized treatments, 19 expanded indications for existing personalized medicines, and 17 significant new or expanded indications for 12 diagnostic testing products. As a result, the increasing approvals for personalized medicines are contributing to the growth of the arthritis monoclonal antibody market.

Major companies operating in the arthritis monoclonal antibody market are introducing new biosimilar products, such as Hulio, to improve treatment affordability and accessibility. Hulio is a biosimilar version of AbbVie’s widely used rheumatoid arthritis drug Humira. For instance, in July 2023, Biocon Biologics, an India-based subsidiary of Biocon Limited focused on biosimilar development, launched Hulio (adalimumab-fkjp), a biosimilar alternative to Humira. This monoclonal antibody therapy, indicated for conditions including rheumatoid arthritis and psoriatic arthritis, was introduced at a price approximately 5% lower than Humira, which is listed at $6,922 per carton.

In May 2023, Abiogen Pharma Spa, an Italy-based pharmaceutical company, acquired EffRx Pharmaceuticals SA for $8.77 million. The acquisition of a majority stake in EffRx aligns with Abiogen’s growth strategy by supporting international expansion and reinforcing its commitment to addressing osteoarticular and bone metabolism disorders. EffRx Pharmaceuticals SA is a Switzerland-based pharmaceutical company engaged in the treatment of various conditions, including arthritis.

Major companies operating in the arthritis monoclonal antibodies market are Johnson & Johnson, Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., AbbVie Inc., Amgen Inc., Genentech Inc., GlaxoSmithKline plc., AstraZeneca plc, Bristol Myers Squibb, Eli Lilly and Company, Thermo Fisher Scientific Inc., Sanofi SA, Daiichi Sankyo Company Ltd., Seattle Genetics, Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Corp., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., HanAll Biopharma Co. Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, Regeneron Pharmaceuticals Inc., Samsung Bioepis Co. Ltd.

North America was the largest region in the arthritis monoclonal antibodies market in 2025. The regions covered in the arthritis monoclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the arthritis monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the arthritis monoclonal antibodies market by increasing costs associated with imported biologic drugs, active pharmaceutical ingredients, and cold-chain logistics. Hospital procurement and branded biologics in regions such as North America and Europe are most affected due to reliance on global manufacturing networks. These cost pressures may limit short-term accessibility; however, tariffs are also encouraging local biologics manufacturing, biosimilar development, and regional supply chain strengthening, supporting long-term market sustainability.

The arthritis monoclonal antibodies market research report is one of a series of new reports that provides arthritis monoclonal antibodies market statistics, including arthritis monoclonal antibodies industry global market size, regional shares, competitors with a arthritis monoclonal antibodies market share, detailed arthritis monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the arthritis monoclonal antibodies industry. This arthritis monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Arthritis monoclonal antibodies are a class of advanced biological therapies used to treat rheumatoid arthritis and other immune-mediated inflammatory disorders. These medicines work by inhibiting inflammatory proteins such as interleukin-6, thereby reducing joint pain, swelling, and other symptoms associated with inflammation. They also suppress certain immune responses, which helps prevent the body from attacking transplanted organs following surgery.

The primary drugs in the arthritis monoclonal antibodies category include Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, and Remsima. Remicade is a prescription medication used for patients with moderately to severely active Crohn’s disease who have not responded adequately to other treatments. These drugs are used for various applications including rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, and others, and are utilized across sectors such as hospitals, research institutes, and others.

The arthritis monoclonal antibodies market consists of sales of infliximab, adalimumab, golimumab, and certolizumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.